Edition:
United States

Acer Therapeutics Inc (ACER.OQ)

ACER.OQ on NASDAQ Stock Exchange Capital Market

17.28USD
23 Feb 2018
Change (% chg)

$-0.88 (-4.83%)
Prev Close
$18.16
Open
$18.30
Day's High
$18.30
Day's Low
$17.28
Volume
3,642
Avg. Vol
5,950
52-wk High
$21.71
52-wk Low
$5.70

Latest Key Developments (Source: Significant Developments)

Acer Therapeutics Announces Closing Of Underwritten Public Offering Of Common Stock
Thursday, 14 Dec 2017 04:01pm EST 

Acer Therapeutics Inc ::ACER THERAPEUTICS ANNOUNCES CLOSING OF UNDERWRITTEN PUBLIC OFFERING OF COMMON STOCK.  Full Article

Acer Therapeutics Announces Pricing Of Underwritten Public Offering Of Common Stock
Tuesday, 12 Dec 2017 09:00am EST 

Dec 12 (Reuters) - Acer Therapeutics Inc ::ACER THERAPEUTICS ANNOUNCES PRICING OF UNDERWRITTEN PUBLIC OFFERING OF COMMON STOCK.ACER THERAPEUTICS INC - ANNOUNCED PRICING OF ITS UNDERWRITTEN PUBLIC OFFERING OF 916,667 SHARES OF COMMON STOCK AT $12.00/SHARE.  Full Article

Acer Therapeutics Announces Proposed Underwritten Public Offering Of Common Stock
Monday, 11 Dec 2017 04:01pm EST 

Dec 11 (Reuters) - Acer Therapeutics Inc ::ACER THERAPEUTICS ANNOUNCES PROPOSED UNDERWRITTEN PUBLIC OFFERING OF COMMON STOCK.ACER THERAPEUTICS INC - INTENDS TO USE NET PROCEEDS FROM OFFERING TO FUND RESEARCH AND DEVELOPMENT EFFORTS, TO SEEK REGULATORY APPROVAL FOR EDSIVO.ACER THERAPEUTICS INC - ALSO INTENDS TO USE NET PROCEEDS FROM OFFERING TO INVEST IN PRE-COMMERCIAL ACTIVITIES FOR EDSIVO, AMONG OTHERS.  Full Article

Acer Therapeutics Q3 loss per share $1.09
Monday, 13 Nov 2017 04:05pm EST 

Nov 13 (Reuters) - Acer Therapeutics Inc ::Acer Therapeutics reports third quarter 2017 financial results and provides corporate update.Q3 loss per share $1.09.  Full Article

Acer Therapeutics raises $15.7 million in Equity Financing
Wednesday, 4 Oct 2017 02:05pm EDT 

Oct 4 (Reuters) - Acer Therapeutics Inc :Files to say that it has raised $15.7 million in Equity financing-SEC filing‍​.  Full Article

Acer Therapeutics reports positive results from clinical trial of medicine for connective tissue disorder
Monday, 25 Sep 2017 08:30am EDT 

Sept 25 (Reuters) - Acer Therapeutics Inc ::Acer Therapeutics reports positive results from pivotal clinical trial of edsivo™ (celiprolol) for treatment of vascular ehlers-danlos syndrome.Acer Therapeutics Inc - ‍company intends to file NDA for edsivo™ in first half of 2018​.Acer Therapeutics Inc - retrospective source verified analysis of trial data confirmed data from previously published clinical study of celiprolol​.  Full Article

Opexa Therapeutics reports qtrly loss per share $0.09
Monday, 14 Aug 2017 08:08am EDT 

Aug 14 (Reuters) - Opexa Therapeutics Inc :Qtrly loss per share $0.09.  Full Article

Opexa therapeutics Inc says subsidiary Opexa Merger Sub to merge with Acer Therapeutics
Monday, 3 Jul 2017 06:44am EDT 

July 3 (Reuters) - Opexa Therapeutics Inc :Opexa Therapeutics Inc - on june 30, co, Opexa Merger Sub , and acer therapeutics entered into an agreement and plan of merger and reorganization.Opexa Therapeutics Inc - co's subsidiary Opexa Merger Sub to merge with and into Acer Therapeutics, with Acer becoming wholly-owned subsidiary of co.Opexa Therapeutics -at closing of deal, each outstanding share of Acer stock to be converted to right to receive about one share of stock of co.Opexa Therapeutics - following merger, co shareholders expected to own approximately 11.2% of the combined company.Opexa-After deal,current Acer shareholders expected to own about 63.8% of combined co,investors participating in financing expected to own about 25%.Opexa Therapeutics Inc - deal for approximately $15.7 million.  Full Article

Opexa Therapeutics reports Q2 loss per share $0.30
Thursday, 11 Aug 2016 04:01pm EDT 

Opexa Therapeutics Inc : Opexa Therapeutics reports second quarter 2016 financial results and provides corporate update . Q2 loss per share $0.30 .Q2 earnings per share view $-0.23 -- Thomson Reuters I/B/E/S.  Full Article

Opexa Therapeutics Q1 loss per share $0.31
Thursday, 12 May 2016 04:01pm EDT 

Opexa Therapeutics Inc : Opexa therapeutics reports first quarter 2016 financial results and provides corporate update .Q1 loss per share $0.31.  Full Article

BRIEF-Acer Therapeutics Q3 loss per share $1.09

* Acer Therapeutics reports third quarter 2017 financial results and provides corporate update